Pentoxifylline and its applications in dermatology

Hassan, Iffat; Dorjay, Konchok; Anwar, Parvaiz

doi:10.4103/2229-5178.142528

Cited by 50 publications

(41 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, combination therapy with pentoxifylline and tocopherol (vitamin E) has significantly reversed RIF in animal studies, as well as in one double‐blind placebo‐controlled clinical trial. Pentoxifylline is a methylxanthine derivative that increases blood flow and has antifibroblast properties, whereas tocopherol is an antioxidant that combats ROS activity. In vitro studies using irradiated dermal fibroblasts showed a reduction in ROS generation and DNA damage with this treatment.…”

Section: Hypoxia and Oxidative Stress In Radiation‐induced Fibrosismentioning

confidence: 99%

Lipotransfer for radiation-induced skin fibrosis

Kumar

Adigbli

Kalavrezos

et al. 2016

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Hypoxia and Oxidative Stress In Radiation‐induced Fibrosismentioning

confidence: 99%

Lipotransfer for radiation-induced skin fibrosis

Kumar

Adigbli

Kalavrezos

et al. 2016

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Due to the role of TNF‐α in SPD pathology, the patient was subsequently treated with the TNF‐α inhibitor Pentoxifylline. Pentoxifylline has been shown to suppress TNF‐α production in both animal and human models and has been previously used for the treatment of claudication and as well as other dermatological conditions including psoriasis, aphthosis, lipodermatosclerosis, and actinic prurigo (Hassan, Dorjay, & Anwar, ). Adverse reactions from the medication are minimal and rare but most commonly include gastrointestinal effects such as nausea.…”

Section: Discussionmentioning

confidence: 99%

Pentoxyfilline as a treatment for subcorneal pustular dermatosis

Falcone

Pilcher

Kovach

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Subcorneal pustular dermatosis (SPD) is a rare pustular neutrophilic dermatosis in which groups of sterile pustules appear in the superficial (subcorneal) skin. This chronic condition can be associated with significant morbidity and decreased quality of life. Dapsone is the first‐line therapy for SPD, but some patients fail to respond or cannot tolerate it. In these instances, patients may be treated with second‐line therapies such as phototherapy, topical corticosteroids, or systemic agents including glucocorticoids, acitretin, immunosuppressive, or biologic medications. These therapies may not always be efficacious and can be associated with intolerable adverse effects. Here, we report a case of a patient who sustained long‐term remission and no side effects with the novel use of pentoxifylline, a tumor necrosis factor‐alpha inhibitor, as monotherapy. Pentoxifylline should be considered as a possible therapy in patients with SPD intolerant to dapsone.

show abstract

“…Trental (pentoxifylline), a methylxanthine derivative, imparts a variety of anti-inflammatory effects (Hassan et al 2014) and was begun to be more widely investigated for its potential use in treating BD starting in the mid-1990s (see Arici et al 1997;Hamuryudan et al 1997, Wolchok 1997Pizarro et al 2000;Hassard et al 2001). Pentoxifylline acts as an immunomodulant in that while it can cause increases in leukocyte deformability and chemotaxis, more importantly, it can induce decreases in neutrophil degranulation, endothelial leukocyte adhesion, activation of T-and B-cells, natural killer (NK) cell activity, release of superoxide and other ROS, monocyte production of select cytokines (e.g.…”

Section: Dapsone 100 Mg/d 3 Momentioning

confidence: 99%

Genetics and immunodysfunction underlying Behçet’s disease and immunomodulant treatment approaches

Salmaninejad

Gowhari

Hosseini

et al. 2017

Journal of Immunotoxicology

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic autoimmune condition primarily prevalent in populations along the Mediterranean Sea. The exact etiology of BD has not been fully explained yet, but the disease occurrence is associated with a genetic factor, human leukocyte antigen (HLA)-B51 antigen. Among the various immunodysfunctions that are found in BD, patients are increased neutrophil motility and superoxide production, as well as elevated production of tumor necrosis factor (TNF)-α and decreased production of interleukin (IL)-10. Elevated levels of inflammatory cytokines like IL-1 and IL-17 in BD have been found associated with aberrant expression of microRNA. Gene polymorphisms in BD patients have been observed in molecules involved in responses to pathogens that can ultimately modulate the host antimicrobial response. Moreover, several single nucleotide polymorphisms (SNPs) have been reported in genes encoding chemokines and adhesion molecules; many of these changes manifest as increases in vascular inflammation and vascular damage. Lastly, genetic and epigenetic changes have been suggested as involved in the pathogenesis of BD. Modifications in DNA methylation have been found in BD patient monocytes and lymphocytes, leading to adverse function of these cells. This review presents a comprehensive compilation of the literature with regard to the immunodysfunction underlying BD, as well as of the genetics, newly described clinical specifications and novel treatment strategies using immunomodulants based on the current understanding of BD.

show abstract

Pentoxifylline and its applications in dermatology

Cited by 50 publications

References 60 publications

Lipotransfer for radiation-induced skin fibrosis

Lipotransfer for radiation-induced skin fibrosis

Pentoxyfilline as a treatment for subcorneal pustular dermatosis

Genetics and immunodysfunction underlying Behçet’s disease and immunomodulant treatment approaches

Contact Info

Product

Resources

About